loader2
Login OPEN ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

SENORES PHARMACEUTICALS SHARE PRICE

Sector Pharmaceuticals
BSE 544319
NSE SENORES
₹1,090.80
-22.10 (-1.99 %)
Buy
B
Sell
S
NSE BSE

Overview

1D 1W 1M 3M 6M 1Yr 3Yr 5Yr 10Yr Max
Price PE Ratio
 

We appreciate your patience. Your content is on the way.

Day Low

1,084.60

Day High

1,123.90

52 Week Low

706.00

52 Week High

1,599.00

All Time Low

435.25

All Time High

1,599.00

Open

1,112.90

Close

1,112.90

Volume

209,917

Mkt cap (Cr)

5,023.57

P/E ratio

36.61

P/B ratio

5.01

Div yield

0.00%

6M return

3.24%

1Y return

37.91%

SWOT Analysis

  • S
  • W
  • O
  • T

Technical Analysis

Moving Averages

EMA SMA
 

We appreciate your patience. Your content is on the way.

1,090.80 -1.99%

Current Price

Tech Pointer
  • Bullish Moving Averages
  • Bearish Moving Averages

Resistance and support

 

We appreciate your patience. Your content is on the way.

Company Financials

  • Profit and loss statement
  • Balance sheet
  • Quarterly Result
  • Ratio
 

We appreciate your patience. Your content is on the way.

Quick Results Snapshot

 

We appreciate your patience. Your content is on the way.

Shareholding Pattern

Summary

 

We appreciate your patience. Your content is on the way.

 

We appreciate your patience. Your content is on the way.

Historical Promoter Summary

 

We appreciate your patience. Your content is on the way.

Promoter Holding(%)

Historical FII Holdings

 

We appreciate your patience. Your content is on the way.

FII Holding(%)

Historical MF Holdings

 

We appreciate your patience. Your content is on the way.

MF Holding(%)

Stocks Comparison
Table Chart

 

We appreciate your patience. Your content is on the way.

Corporate Action

  • Announcement
  • Board Meeting
  • Dividend
  • Split
  • Rights
  • Events

Insider & Institutional Activity

  • Bulk Block Deals
  • Insider Trading & SAST
 

We appreciate your patience. Your content is on the way.

About Senores Pharmaceuticals Ltd

Stock PE (TTM)

36.61

Promoter Holding

45.82%

Book Value

217.7862

ROCE

4.17%

ROE

2.78%

Senores Pharmaceuticals Limited was originally incorporated as "Senores Pharmaceuticals Private Limited" dated December 26, 2017, issued by the office of Central Registration Centre. Thereafter, the name was changed to "Senores Pharmaceuticals Limited" upon conversion to a Public Limited Company dated September 4, 2023. Senores Pharma is a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for Regulated Markets across various therapeutic areas and dosage forms. The Regulated Markets business is focused on Regulated Markets of US and Canada. The Company has adopted a strategy of identifying, developing and commercializing specialty and complex niche products in the mid-market range and received approvals for 19 ANDAs. Further, it develop and manufacture pharmaceutical products across various therapeutic areas for Emerging Markets, having a presence across 43 countries. The Company operate a Critical Care Injectables Business, supplying critical care injectables to hospitals across India through distributors, and manufacture APIs for the domestic market and SAARC countries. In 2021, the Company incorporated a wholly owned subsidiary, Senores Pharmaceuticals Inc in the US. It then entered the new segment of API by acquiring Ratnagene Lifescience Private Limited. The Company started domestic business with the launch of the Critical Care Injectables Business in 2022. The Company further acquired majority stake in Havix Group Inc., making it a subsidiary of the Company in 2023. It consolidated presence in emerging markets by acquiring shares in Ratnatris Pharmaceuticals Private Limited, making it a Subsidiary of the Company in 2023. The Company has launched CMO product in the US with Jubilant Cadista Pharmaceuticals Inc., in 2024. The Company launched the IPO of 14,887,723 Equity Shares of face value Rs 10 each, by raising money aggregating to Rs 582.11 Crore, comprising a fresh issue of 12,787,723 equity shares amounting to Rs 500 Crore and the offer for sale of 2,100,000 equity shares amounting to Rs 82.11 Cr in December, 2024. The Company has commenced manufacturing activities at its greenfield API plant located in Gujarat in FY 2025. In FY 2025-26, the Company acquired a 75% stake in Apnar Pharma Private Limited, including its USFDA-approved facility in Jambusar, Gujarat in 2026. Further, the Company acquired a 51% membership interest in Zoraya Pharmaceuticals LLC, a US based entity through Senores Pharmaceuticals Inc., the Company`s wholly owned subsidiary in November 2025.

Senores Pharmaceuticals share price as on 23 Nov 2026 is Rs. 1090.8. Over the past 6 months, the Senores Pharmaceuticals share price has increased by 3.24% and in the last one year, it has increased by 37.91%. The 52-week low for Senores Pharmaceuticals share price was Rs. 706 and 52-week high was Rs. 1599.

Read More
Registered Office  
Registrars  
Management  
Listing Info  

544319

SENORES

INE0RB801010

Sep

Senores Pharmaceuticals Ltd FAQs

You can buy Senores Pharmaceuticals Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Senores Pharmaceuticals Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Nov 20, 2026 03:57 PM the closing price of Senores Pharmaceuticals Ltd was Rs.1,090.80.

The latest PE ratio of Senores Pharmaceuticals Ltd as of Nov 20, 2026 03:57 PM is 36.61

The latest PB ratio of Senores Pharmaceuticals Ltd as of Nov 20, 2026 03:57 PM is 5.01

The 52-week high of Senores Pharmaceuticals Ltd share price is Rs. 1,599.00 while the 52-week low is Rs. 706.00

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Nov 20, 2026 03:57 PM, the market cap of Senores Pharmaceuticals Ltd stood at Rs. 5,023.57 Cr.

Market Outlook

View all
 

We appreciate your patience. Your content is on the way.